CIAS
TXMD icon

Capital Investment Advisory Services’s TherapeuticsMD TXMD Stock Holding History

Capital Investment Advisory Services’s Portfolio TXMD Stock Details TXMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-14
Closed -$3K – 1213
2019
Q3 		$3K Hold
14
– – ﹤0.01% 1237
2019
Q2 		$2K Buy
+14
New +$2.51K ﹤0.01% 1306

Other funds holding TXMD

JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
FCM
Frontier Capital Management Boston, Massachusetts $9.73B AUM 55.65% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Capital Investment Advisory Services's TXMD Position: Q4 2019 in Review

Capital Investment Advisory Services sold out of TherapeuticsMD (TXMD) in Q4 2019, closing a stake of 14 shares — an estimated $3K sold.

Capital Investment Advisory Services first reported a position in TXMD in Q2 2019 and held it in 2 quarters. The position peaked at $3K in Q3 2019. 168 funds tracked by Wall St. Rank hold TXMD as of Q4 2019.

  • Capital Investment Advisory Services reported no remaining TherapeuticsMD position as of Q4 2019 after selling out during the quarter.
  • Capital Investment Advisory Services sold 14 TherapeuticsMD shares in Q4 2019, an estimated $3K.
  • Capital Investment Advisory Services first reported a position in TherapeuticsMD in Q2 2019 and held it in 2 quarters.
  • Capital Investment Advisory Services's TherapeuticsMD position peaked at $3K in Q3 2019.
  • 168 funds tracked by Wall St. Rank held TherapeuticsMD as of Q4 2019.

Based on Capital Investment Advisory Services's 13F filing for Q4 2019, filed 4 Feb 2020.